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INTRODUCTION 
 
Prostate-specific antigen (PSA) is the most clinically useful 
tumour marker available today for the diagnosis and management 
of prostate cancer; unlike other tumor markers prostate specific 
antigen is not cancer specific. Overlapping serum PSA 
concentrations between benign prostatic hyperplasia and 
prostatic adenocarcinoma limit the effectiveness of serum PSA in 
detecting early prostate cancer. 
 
Several concepts have been devised to optimize the 
diagnostic value of serum PSA. Various PSA relation markers 
have been advocated for the differentiation between benign 
prostate hypertrophy and carcinoma in so called "gray zone" 
level of total PSA.    
 
 
  
Age specific PSA reference ranges provide greater 
sensitivity for cancer detection in younger men at the expense of 
a greater negative biopsy rate. In older men unnecessary biopsies 
could be spared. 
 
Studies 32,35,42,44 have reported varying concentrations of 
PSA in serum of healthy males belonging to different races. 
There are very few Indian studies only. Hence we deliberately 
felt it was essential to establish our own age specific reference 
ranges.  
     
 
 
           
 
AIM 
    
 
 
To determine age-specific reference ranges for serum prostate-specific 
antigen (PSA) concentration in South Indian men.  
 
 
 
 
 
 
 
 
 
 REVIEW OF LITERATURE  
 
PSA is a serine protease secreted exclusively by the 
epithelial cells of the prostate and also in minute quantities by 
the epithelial lining of periurethral glands. Its major 
physiological role is to promote the liquefaction of seminal clot. 
It is androgen regulated and one of the most abundant serine 
protease in the seminal plasma (1,000,000 ng/ml) 
 
History 24 
 
In 1970, Ablin R.J. et al.2 identified two separate prostatic 
tissue-specific antigens. One of the antigens was identified, as 
prostatic acid phosphatase, while the other, the forerunner of the 
current PSA remained unnamed. In 1971, Hara et al. identified a 
protein in seminal fluid. They called it gamma-seminoprotein. 
 
A few years later (1979) Wang, Chu et al. purified the 
antigen from prostatic tissue and named it prostate-specific 
antigen.  
 Papsidero and associates detected PSA in human serum in 
1980. These researchers were the first to demonstrate the 
relationship of PSA to prostate cancer. 
 
Because PSA is produced by the body and can be used to 
detect disease, it is sometimes called a biological marker or 
tumor marker. Prostatic intraepithelial neoplasia does not cause 
disruption of the basement membrane and does not raise serum 
PSA. 
 
PSA paradox 37 
 
  Normal prostate epithelial cells and benign hyperplastic 
tissue produce more PSA than malignant prostatic tissue. In 
localized and metastatic prostate cancer the expression of PSA 
per cell is reduced, but there is an increase in the level of serum 
PSA. Malignancy is typically associated with a lower degree of 
differentiation; therefore the relative number of terminally 
differentiated cells will decline, as well as the expression of 
differentiation markers such as serum PSA. Malignancy results 
in loss of polarity and basal cell numbers and disruption of 
basement membrane, leakage of PSA to circulation. 
 In prostate cancer, serum PSA is determined by the number 
of cancer cells and the expression of PSA per cancer cell. 
Considering the more aggressive cancer cells produce less PSA, 
the phenomena counteract one another. This explains why PSA is 
a poor marker in cancer progression 
 
Nonprostatic sources of PSA 
 
The name PSA reflects the initial widespread belief that 
expression of the protein was restricted to the prostate gland. 
However this notion has been dispelled. Numerous studies have 
shown that PSA is expressed extraprostatically. Low levels of 
PSA3 have been detected in various tissues that express steroid 
receptor super family, including uterine endometrium, breast 
tissue, peri anal & peri uretheral glands, salivary glands, adrenal 
and renal neoplasm’s and various other malignant tumours. In 
1993 Iwakini et al54. showed PSA secretion from periurethral 
glands by immunohistochemical studies. Oesterling8 et al 
suggested that the periurethral glands do not have a clinically 
significant effect on serum PSA concentration after radical 
prostatectomy.  
 Growth and Development of Human Prostate9: 
 
Human prostate undergoes an increase in size and develops 
histological evidence of stimulated growth during three periods 
of life9. Before and at birth, during puberty, with advancement of 
age. The average weight of prostate is as follows 
1 to 10 years  – 1.4   g,  
11 to 20 years - 10.8 g, 
 21 to 30 years - 18.g,  
41 to 50 years - 20.2g.  
In 6th decade 30.9   
8th decade to 38.8 g    
 
The prostate-specific antigen (PSA) test 
 
Gutman and Gutman in 1938, described acid phosphates as 
a tumour marker for prostatic cancer. Acid phosphatase was 
replaced by serum PSA because of its low sensitivity and 
specificity. A PSA test measures the amount of prostate-specific 
antigen in the blood. Low amounts of PSA may be found in the 
blood of healthy men. The amount of PSA in the blood normally 
increases as a man's prostate enlarges with age. It is also 
 increased by inflammation of the prostate gland, prostate cancer, 
manipulation, and urinary retention 
 
Prostate-specific antigen test is done to determine whether 
lumps found during a digital rectal exam or a transrectal 
ultrasound may be caused by prostate cancer, to monitor the 
development of prostate cancer and the response to treatment. If 
PSA levels are increasing, the cancer may be growing or 
spreading. Successful treatment of prostate cancer usually causes 
PSA levels to drop. The amount of PSA is often undetectable in a 
man who has been treated for prostate cancer by having his 
prostate gland removed. PSA levels that rise after prostate 
removal indicate that the cancer may have spread to another part 
of the body or has recurred at the prostate site.  
 
Commercial Assays:  
 
Commercial PSA assays measure the glycoprotein in the 
serum using immuno- assays. It is important that the assay be 
performed in the same laboratory for comparative purposes over 
time. Some assays are immunoradiometric and some are enzyme-
immunoassays the importance of the PSA test in early detection 
 is based on establishing a baseline value and doing the PSAs 
over time on a regular interval, usually one year.  
Assay kits for total PSA                                                       
Table - 1 
Assay kit Capture antibody Tracer antibody 
Minimal detectable 
limit (micro gram/L) 
Bayer 
ADVIA 
centaur 
m Sh (Sheep poly clonal) 0.06 
Can Ag 
ELISA m m 0.10 
CIS ELSA-2 m m (monoclonal) 0.14 
 
 
Advice to the patient  
1. Refrain from sexual activity for 2 to 3 days prior to testing.  
2. To wait for one week after having a cystoscopy29. (Baseline 
level reached in 3 days) 
3. To wait until a urinary tract infection or prostatitis has 
cleared up. 
4. To wait for 6 weeks29 after a needle biopsy or TUR before 
doing PSA test  
 
 
 
 Inaccurate test results: 
1. Recent sexual activity or a cystoscopy test may cause 
prostate-specific antigen (PSA) levels to rise. Osterling and 
colleagues57 prospectively randomized 69 men into 3 
group’s flexible cystoscopy, rigid cystoscopy and control. 
Two serum PSA levels were estimated. They found the 
median serum PSA after flexible cystoscopy was 0.1ng/ml, 
rigid cystoscopy and control was 0.05ng/ml. 
2. Large doses of some medications used to treat cancer—such 
as cyclophosphamide diethylstilbestrol, and methotrexate - 
can interfere with test results.  
3. The medication finasteride, used to prevent further 
enlargement of the prostate gland in men with benign 
prostatic hypertrophy (BPH), can cause inaccurately low 
PSA levels. Finastride24 decreases total PSA and PSA 
density; free PSA is not affected.  
4. Herbal supplements can also affect PSA levels. 
5. Contamination or inadequate refrigeration of the blood 
sample can cause inaccurate test results. 
  
  
DEFINITIONS.  
 
Sensitivity: Is the capability of a test to identify the presence of 
disease expressed as the ratio of true positives to the sum of true 
positives and false negatives. . PSA has a sensitivity of 80%. 
 
Specificity: Is the capability of a test to identify the absence of 
disease expressed as the ratio of true negatives to the sum of true 
negatives and false positives.  PSA has a specificity of 35-50%. 
 
Positive predictive value: Is the capability of a test to identify 
patients with disease among all patients demonstrating positive 
results.  
False positive test: 
False positive test results occur when the PSA level is 
elevated but no cancer is actually present. False positives may 
lead to additional medical procedures that have potential risks 
and significant financial costs and can create anxiety for the 
patient and his family. Most men with an elevated PSA test turn 
out not to have cancer. Only 25 to 30 percent of men who have a 
 biopsy due to elevated PSA levels actually have prostate cancer. 
In general 5-8 percent of a screening population will have an 
abnormal DRE. A value between 4-10 ng/ml has a 15-30% 
chance of being positive. Values above 10 are associated with a 
positive biopsy in greater than two thirds of cases upper limit of 
normal for PSA is controversial. Recent studies23suggest that 
using a PSA cutoff of 2.5 ng/ml for men younger than 60 years 
may be more appropriate.  
 
False negative tests: False negative test results occur when 
the PSA level is in the normal range even though prostate cancer 
is actually present. Most prostate cancers are slow growing and 
may exist for decades before they are large enough to cause 
symptoms. Subsequent PSA tests may indicate a problem before 
the disease progresses significantly. Cancers missed by the age 
specific reference ranges in older men (>69 years) were 
predominantly small, organ confined, unlikely to be life-
threatening 25 and avoids invasive prostatic biopsies.       
           
 
 Strategies for enhancing Prostate specific antigen specificity; 
                
Attempts to improve the specificity of serum PSA determinations 
as a risk indicator for prostate cancer have focused on the 
following approaches; 
 
1. Age specific PSA  
2. PSA density 
3. PSA velocity 
4. PSA transition zone density 
5. Free to total PSA ratio 
6. ACT alpha 1 complex PSA                                                          
 
Age specific reference ranges. 
 
 
       PSA is also age dependent, studies2 5 have shown that age 
was found to contribute independently of volume to serum PSA, 
accounting for 5% of variance in serum PSA concentration. 
PSAD correlates directly with age. Factors intrinsic to the aging 
prostate play a role in the variation serum PSA with advancing 
age. Osterling et al55, showed the clinical usefulness of age 
specific PSA by noting an increase in specificity by 11% and 
positive predictive value by 5%.  
 Osterling et al56, have concluded that when age specific 
reference ranges were used PSAD does not contribute additional 
information. Data has shown 96% agreement between PSA and 
PSAD.  
 
Age specific reference range sensitivity: 
 
 
Studies have shown that age specific reference ranges 
decrease the sensitivity of PSA in older men (>6o years) but 
improve it younger men. 
 
Criley SR et al26 has reported that age specific reference 
ranges increase the potential for detection of prostate cancer by 
18% in men 50 years old or younger and decreased detection by 
19% in men 69 years old or older. The following is a guideline 
adjusted for age3. 
Age 40-49       0.0-2.5 ng/ml 
Age 50-59       0.0-3.5 ng/ml 
Age 60-69       0.0-4.5 ng/ml 
Age 70-79       0.0-6.5 ng/ml 
 
 
 
  
 
 
Age specific reference range according to individual year of life 25.  
(Table -2) 
 
                                             
                                                 Table – 2  
 
 
    Age                      PSA range 
   Years                         ngs/ml 
    Age                      PSA range 
   Years                         ng/ml 
40 2.0 
41 2.1 
42 2.2 
43 2.3 
44 2.3 
45 2.4 
46 2.5 
47 2.6 
48 2.6 
49 2.7 
50 2.8 
51 2.9 
52 3.0 
53 3.1 
54 3.2 
55 3.3 
56 3.4 
57 3.5 
58 3.6 
59 3.7 
60 3.8 
61 4.0 
62 4.1 
63 4.2 
64 4.4 
65 4.5 
66 4.6 
67 4.7 
68 4.9 
69 5.1 
70 5.3 
71 5.4 
72 5.6 
73 5.8 
74 6.0 
75 6.2 
76 6.4 
77 6.6 
78 6.8 
79 7.0 
 
  Algorithm for the use of age specific reference ranges:  25  
(Table – 3) 
 
                                                      Table – 3(25) 
 
PSA DRE DIAGNOSTIC ACTION 
Less than or equal to 
age specific range Negative  
Annual PSA, DRE 
Greater than age 
specific range 
Negative TRUS; biopsy visible 
lesions, systemic 
sextant biopsy, with 
two cores containing 
transition zone 
Any value Positive  TRUS; biopsy palpable 
and visible lesions, 
sextant biopsy of 
remaining prostate 
 
 
The normal 4.0 ng/ml is no longer recognized as the cutoff 
point. A recent study has reported that 15% of men with a normal 
DRE and a PSA level of < 4ng /ml have cancer detected on 
systemic needle biopsies. The current American cancer society 
and the 2004 National Comprehensive Cancer Center Network 
guidelines also recommend considering a biopsy for a PSA level 
of > 2.5 ng / ml 23. 
 
 It is important to recognize that the real value of the PSA 
test in early detection is based on establishing a baseline PSA 
value and regularly, on a yearly basis, measuring the PSA to 
observe changes from the baseline value. Incremental changes of 
0.75 ng/ml in a year should be investigated. 
Catolona WJ et al 23 said that a trend is more important 
than any single PSA value and one must always remember that 
PSA is not specific for cancer. 
  
Age adjusted PSA.  
 
Concept of raising PSA threshold in older patients and 
lowering it in younger patients. Data suggests normal PSA of 2.5 
may be more appropriate in men under the age of 60. Many 
suggest lowering value for young men and maintaining 4.0 for 
older patients to minimize "miss rate" in this population  
 
PSA density  
 
Benson et al4 9 introduced the term PSA density to correct 
PSA for prostatic volume. PSA density is the value of the PSA 
divided by the size of the prostate. The likelihood of prostate 
cancer is increased when the PSAD value is high.  
 Prostate biopsy is recommended in men with normal DRE, 
PSA between 4 to 10 ng /ml and PSAD of 0.15 or greater   The 
use of PSA density 13 to interpret PSA results is controversial 
because cancer might be overlooked in a man with an enlarged 
prostate.  
 
Recent large studies conducted by Brawer and associates4 7 
have not confirmed the utility of PSA density. Catalona and 
associates4 8 documented that approximately 50 % of CaP would 
have been missed using a cut off of 0.15, this may be due to 
difficulty in obtaining reproducible prostatic volume by TRUS. 
 
PSA transition zone density3 8  
 
 
Transition zone adjusted PSA were used in an attempt 
improve the specificity of prostate cancer. Calculated threshold 
for transition zone PSA density of 0.35 ng/ml provided the 
highest positive predictive value for prostate cancer detection in 
patients with tPSA <10 ng /ml. Because of the greater variability 
in the determination of PV the use of transition zone PSA density 
remained as an investigational tool for early detection of prostate 
cancer.  
  
 
PSA velocity:  
 
 
PSA velocity is based on changes in PSA levels over time. 
Carter and colleagues5 0 in a long term prospective study found 
the average rate of change of serum PSA over three consecutive 
PSA determinations had a better specificity (90 %) for detecting 
prostatic cancer as compared to 60 % when PSA greater than 4 
ng/ml was the detection criteria. A sharp rise in the PSA level 
raises the suspicion of cancer.  PSA levels appear to increase 
more slowly in men with prostate enlargement. 
The rate of changes in the PSA5 0 more than 0.75 ng/ml per 
year was a specific marker for cancer. PSA velocity cut offs have 
not been determined for men with PSA values less than 4 ng/ml. 
Less 5% of men with out a history of prostate cancer have PSA 
velocity of more than 0.75 ng/ml/y. 
Carter et al21, suggested a minimum length of follow up of 
18 months is needed to use PSA velocity for cancer detection. 
The test is used as a tool to keep track of how PSA levels 
change, but it is not used to diagnose prostate cancer.   
 If PSA increases dramatically in a short period, it may be 
one indicator that prostate cancer has progressed. 
  
Recent study by D'Amico et al5 published in the New 
England Journal of Medicine suggested that an annual PSA 
velocity of 2 ng/ml or greater was independently associated with 
prostate cancer mortality after radical prostatectomy. Potentially 
this may serve as a marker for identifying patients who may be 
considered for novel neoadjuvant strategies before undergoing 
surgery. 
Molecular forms of PSA 
In 1990, Christensson et al. discovered that PSA exists in 
more than one form circulating in serum. These forms are: Free 
PSA (PSA-f), bound PSA (PSA-ACT) and complexed PSA (PSA-
MG). Most of the PSA in the sera is bound to the antiproteases 
ACT and MG Binding of PSA to ACT inactivates the protease, 
but it is immunodetectable. Since the complexed form, PSA-MG 
is not immunoreactive4; it is not measured by any of the 
available commercial assays at the present time. Total PSA is a 
combination of PSA-f (10- 30 %) and PSA-ACT (65 –90%). 
  
 
 
 
Mechanism of formation of different forms of  PSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Prostate 
 
 Normal or malignant                                   
                                                                         pro PSA                     PSA 
epithelial cells   
                                                                           
                                                    cancer                                     
                                                        
                                                                                                                                 
                                                                     pro PSA                                         
                                                                     isoforms            BPH                           Normal 
                                                                                                                                       BPH     
                                                                                                                                   Cancer 
                                                                                                                           
                      
                     
                                                                                            BPSA 
BLOOD 
  
 
 
 
 
 
 
Pro PSA isoforms +  BPSA = Free PSA 
 
 
 
 
PSA ACT   +   Free PSA  = Clinical Total PSA  
 
 
 
 
Free PSA  +  PSA MG +  PSA ACT =  True total PSA 
  
 
 
 
 
                                                                                                
 
 
Free PSA: 
                  Free PSA in serum3 7 is composed of three distinct 
forms: pro PSA, BPSA, and intact PSA that may have structural 
or conformational changes that makes it inactive. All forms of 
free PSA are enzymatically inactive BPSA, is a degraded form of 
PSA that has been shown to be associated with prostate BPH 
transition zone tissue. 
BLOOD 
 Free PSA (BPSA) concentration is more in benign prostatic 
hyperplasia, while cancer produces more of the attached form. 
This difference may be due to differential expression of PSA 
isoforms by transition zone compared with peripheral zone. 
Cancer produces more of pro PSA. 
In the intermediate PSA range between 4 to 10 ng /ml the 
percentage of free PSA19 provided important information 
regarding the presence of cancer. If percent free PSA is >25% 
the probability of a positive biopsy drops from 15-30 percent to 
5-7%. Percentage of free PSA cut off 25% detected 95% of 
cancers while avoiding 20% unnecessary biopsies .Low free PSA 
values (less than 15%) are more likely to be caused by prostate 
cancer than high free PSA values.  
 Percent free PSA20 and Probability of cancer 
 
 
Free PSA 
Probability of 
Cancer 
Greater than 25% 8% 
20 – 25% 16% 
15 – 20% 20% 
10 – 15% 28% 
0 – 10% 56% 
 
  
The use of f/t PSA has been extensively evaluated and 
found to greatly improve the specificity of prostate cancer 
detection. At 85 % and 95%sensitivity free PSA provided the 
highest Specificity. 
 
Precursor PSA (pPSA).  
 
Molecular form of free PSA. PSA is secreted from the 
prostate luminal epithelial cells as pPSA, an inactive proenzyme 
containing a 7-amino acid pro-leader peptide and 237 amino 
acids of mature PSA. The pro-leader peptide is removed 
extracellularly to produce active, mature PSA. Since no pPSA 
forms have been found in seminal plasma, pPSA has been 
 identified as a serum marker with greater cancer specificity6. 
Precursor –PSA27 has shown some early results in detecting 
prostate cancer at PSA levels of 2 –10 ng/ml  
 
 
Complexed prostate-specific antigen (cPSA) is a fairly new 
test to help detect prostate cancer.  Ozdal et al38  have suggested 
that complexed PSA is similar to the total PSA  in sensitivity but 
complex PSA is more specific than t PSA. Complex PSA alone 
has lower validity than the ratio of free and total PSA. At a 
sensitivity of 90% the cPSA /PV ratio with a threshold of 0.08 
provided the highest specificity. However, at a sensitivity of 95 
% f/tPSA provided the highest specificity38. The cPSA test 
currently is not widely available. As a single test for screening, 
cPSA may improve specificity over total PSA and comparable 
specificity to free-to-total PSA for prostate cancer detection, and 
may reduce the number of unnecessary prostate biopsies in the 
2.6-4.0-ng/mL - tPSA range7. 
 
 
 
 
 Molecular forms of PSA and age; 
 
Following a community based study; Oesterling et al4 6  
concluded that the individual serum concentrations of free PSA, 
total PSA and complexed PSA all correlated with the patient’s 
age. The ratios of free to total PSA, complexed to total PSA, free 
to complexed PSA were constant for men of all ages. Complexed 
and total PSA all correlated directly with the patient’s age. 
 
Risk factor for carcinoma prostate 
 
 
Ries LAG et al58, has shown that age is the most common 
risk factor, with nearly 70 percent of prostate cancer cases 
occurring in men age 65 years and older .The post pubertal 
presence of an intact hypothalamo pituitary testicular axis is 
required for the development of carcinoma prostate. Men 
castrated before onset of puberty have little risk of developing 
carcinoma prostate.  
 
Other risk factors for prostate cancer include family 
history, race30, and possibly diet. Men who have a father or 
brother with prostate cancer have a greater chance of developing 
prostate cancer.  
 Eldon et al3 9 found that female relatives are not at higher 
risk of breast cancer but they may be at greater   risk of kidney 
cancer. African American men have the highest rate of prostate 
cancer4 0, while Asian and Native American men have the lowest 
rates. In addition, there is some evidence that a diet higher in fat, 
especially animal fat, may increase the risk of prostate cancer. 
 
Prostate cancer screening: 
 
  
  Using the PSA test to screen men for prostate cancer is 
controversial31 because it is not yet known if this test actually 
saves lives. Moreover, it is not clear if the benefits of PSA 
screening outweigh the risks of follow-up diagnostic tests and 
cancer treatments. The PSA test may detect small cancers that 
would never become life threatening. This situation, called over 
diagnosis, puts men at risk for complications from unnecessary 
treatment. Despite these controversies PSA monitoring fulfills 
the prerequisites of a screening programme. The estimated 
increase in detection lead time10 is approximately 5 years. 
 
The American Cancer Society, American Radiological 
Association, and American Urological Association recommends 
 early detection with an annual DRE and PSA beginning at age 50 
for all men with a life expectancy greater than 10 years and age 
40 for men of African American race3 0  or a family history of 
prostate cancer. 
 
The 2004 recommendation of a consensus panel from the 
National Comprehensive Cancer Network recommends a baseline 
PSA at age 40 for all men. Those men with a serum PSA equal or 
greater to 0.6 ng/ml (the median PSA for that age group) should 
undergo yearly screening, whereas those with a value less than 
0.6 ng/ml may have another interval PSA at age 45. The same 
rule applies at age 45 
Catalona WJ et al23,  recommends: 
1. Annual PSA testing and a DRE at 40 years 
2. Earlier screening for men with family history 
3. Prospectively monitoring PSA velocity 
4. Biopsies for men with a suspicious DRE, PSA>2.5 ng/ml 
5. Using free PSA, cPSA, PSA density and velocity to 
determine the need for repeat biopsies. 
 
 Recommended frequency of prostate specific antigen 
measurement2 4. 
 
1. Annual PSA for men with normal DRE and a stable PSA of 
less than 4 ng/ml and greater than 2.5 ng/ml 
2. Biannual Screening For Men With a normal DRE and a 
serum PSA of less than 2.5 ng/ml 
 No further screening for PSA level of 1 or less in men aged 65 
years. (Baltimore longitudinal study, needs additional 
observations) 
 
Transrectal Ultrasound (TRUS) 
 
TRUS18 is not recommended as a first line-screening test 
because of its low predictive value for early prostate cancer. The 
Transrectal Ultrasound (TRUS) guided biopsies are clearly 
indicated in men with life expectancy greater than 10 years with 
abnormal DRE with or with out an elevated PSA. (TRUS) guided 
biopsies are advised in men with a normal DRE and an elevated 
PSA.level. Milford ward et al29 had shown that DRE or TRUS 
does not cause statistically significant increase in PSA. 
 
 Newer tests:  
RT- PCR assay 
PCA3 formerly called DD3 is the prostate specific gene28 described to 
date. Using RT-PCR assay, prostate tumors showed a 66-fold up regulation 
of DD3 when compared with normal prostatic tissue. This up regulation was 
found in >95% of prostatic cancer specimen studied. This PCA3 based RT- 
PCR assay was used to identify prostate cancer in urine sediments obtained 
after prostatic massage, sensitivity was found to be 67% negative predictive 
value was 90%. This newer study at this stage appears to improve the 
accuracy of diagnosis and avoid unnecessary biopsies. Further results are 
awaited. 
 
Kallikrein tumor markers 
 
The humen kallikrien gene family encodes three known and 
related proteins:tissue kallilerin ,glandular kallikerin and PSA. 
There is  78% aminoacid homology  between hK2 and PSA. Both 
Hk2 and PSA are expressed in prostatic epithelium. They are 
released in a precursor zymogen form and are under androgen 
regulation. They are present in serum and seminal fluid, and can 
form complexes with endogenous protease inhibitors. 
  
Human kallikerin 2 like PSA is found almost exclusively 
with in the prostate. The expression with in the prostate is lower 
than that of PSA.  Black et al5 1 has found the PSA and hK 2 
ratios in male sera to be 0.1 to 34 and the ratio in seminal plasma 
are 100 to 500.  
 
Takayama et al5 2 believed that human kallikerin 2 plays a 
role in regulating PSA activity. It cleaves the precursor form of 
PSA. The expression of hK2 is higher in more poorly 
differentiated carcinomas than in normal and benign tissues. 
Preliminary evidence suggests that the ratio of hk2 to PSA may 
improve the ability of PSA to identify men with prostate cancer. 
Human glandular kallikrein 2, which belong to the human 
kallikrein family as well as PSA, is expected as a tumor specific 
marker. 
 MATERIALS AND METHODS 
 
 
Study design  
Cross sectional study  
Setting    
This study analyzed the PSA value of 117 subjects with out 
lower urinary tract symptoms during the period October 2003 to 
September 2005 at Government General Hospital. Chennai -3 
 Inclusion criteria 
1. Individuals attending Urology Clinics for minor illness 
2. Normal healthy volunteers   
Exclusion criteria    
1. Subjects with history of lower urinary tract symptoms 
2. Subjects with history of recent urethral instrumentation 
3. Subjects with history of recent catheterization 
4. Patients with history of Prostatitis  
 
Data collection 
 
Our study group consisted of 117subjects belonging to the 
subpopulation of chennai from south India of different age 
groups ranging from 40 to 69 years. Detailed history was taken 
 and a complete clinical examination was done. Blood 
biochemical analysis and urine analysis were done for all 
patients. Ultrasound KUBU, digital rectal examination was done 
in all selected subjects. Complete questionnaire is shown in 
appendix 1 
Serum PSA was estimated29 using ELISA, and Bayer ADVIA 
centaur assay kits (last 25 patients). 
 
Case definitions  
 
Subjects referred to Urology department for evaluation of 
renal cyst, back pain, renal microlith, infertility were included in 
the study. Three patients with renal calculi with out urinary tract 
infection were also included in the study. Healthy volunteers 
(hospital workers, patient’s attenders) after through examination 
and history taking were also included in the study group. 
 
Statistical analysis  
 
Statistical analysis by Student‘t’ test. Confidence intervals 
mean, minimum and maximum values were calculated for each 
 decade of age group. Confidence interval high represents 95th 
percentile value in a given group. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 RESULTS  
  
During the study period October 2003 to September 2005, 
serum total PSA of 117 subjects with out lower urinary tract 
symptoms and any other major clinical illness between the age 
group 40 to 69 years were analyzed. The results are shown in    
table - 4                                                                                           
 
 
 
Table - 4 
 
   
Age  40 –49 y (A) 50-59y (B) 60-69y(C) 
Number 50  56 11 
Mean  0.49 0.99 1.27 
Standard deviation  0.27 0.58 0,71 
Median  0.40 0.77 1.34 
Standard error of 
mean 
0.038 0.077 0.22 
Lower 95% CI 0.416 0.838 0.85 
Upper 95% CI 0.564 1.142 1.69 
Min -Max 0.05 –1.10 0.10-2.30 0.41 –2.20 
Range  1.05 2.20 1.79 
P value A vs. B  = 
0.000 
B vs. C= 
0.190 
F=0.170 
A vs. C = 
0.000 
                                                                                                                                                  
 
  
Using the 95th percentile CI, the recommended age-specific 
reference ranges of total PSA values were as follows: for the age 
group 40 –49 years 0.564 ng/ml, 50-59years 1.142 ng/ml 
respectively, and for the age group 60-69years serum PSA 95th 
percentile value is 1.69 ng/ml. The minimum value of total serum 
PSA detected was 0.05 ng/ml and the maximum value of serum 
PSA was 2.30 ng/ml 
                                                                                                                
The mean PSA value increased from 0.49 for men aged 
between 40 to 49 years to 1.27 for men aged between 60-69 
years. The increase was statistically significant (p =0.000). 
The mean total PSA value increased from 0.99 for men aged 
between 50 to59 years to 1.27 were for men aged between 60 to 
69 years. But the increase was not statistically significant (P 
=0.190), this may be because of the small sample size (9.4%) in 
the age group 60 to 69 years. Serum PSA was detected in the sera 
of all the 117 subjects. 
 DISCUSSION 
 
Total PSA (tPSA) is a widely used tumour marker for the 
early detection and monitoring of patients with prostate cancer. 
While PSA testing has resulted in an increase in prostate cancer 
detection, its routine use has been questioned because of lack of 
specificity.   Racial variations of PSA values were observed. 
 
Studies have shown that race may also be an important 
factor in setting a reference range Enormous efforts were made 
to establish age specific reference ranges through out the world. 
Black men with prostate cancer have higher PSA levels33,40  than 
whites even after adjustment for age and stage of the disease. 
Morgan et al33   showed that using standard age specific reference 
ranges  41 % of cancers were missed in black  men and suggested 
the following reference range for black men; for men in their 
40s, 0 to 2ng/ml, for men in their 50s 0 to 5ng/ml, for men in 
their 60s 0 to 4.5 ng /ml, and 0 to 5.5 ng/ml for men in their 70s. 
 
 Extensive work by osterling3 2 ,  3 5 group on American whites 
and Japanese men clearly showed age specific significant 
increase for 95 percentile with advancing age.  
 Our study also shows age specific significant increase for 
95-percentile value (fig 1) 
 
Age wise PSA
age
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ps
a
2.5
2.0
1.5
1.0
.5
0.0
 
   age psa 
age Pearson Correlation 1 .526(**)
  Sig. (2-tailed) . .000
  N 116 116
psa Pearson Correlation .526(**) 1
  Sig. (2-tailed) .000 .
  N 116 116
             ** Correlation is significant at the 0.01 level (2-tailed). 
 
  
                 Age specific PSA                                        Figure 1 
 
 
  
 
  
 
 
Myrtel5 3 et al found that 100 % of healthy men less than 40 
years and 97 % of men over age 40 had a serum PSA below or 
equal to 4 ng/ml. 
 
Our study shows a similar finding and in none of our 
patients between the age group of 40 –69 serum PSA was more 
than 4 ng/ml.  
 
Studies have shown that age-specific reference ranges for 
serum PSA were significantly lower for Asians than Western men 
15,32,34,41. Our study also shows a low age specific PSA values 
compared to Western men. (Fig.2) 
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(Fig.2) 
 
 
 
Study conducted at the department of biochemistry punjagutta34 India 
has shown the age specific reference ranges were 1.39 for men aged 40-49, 
1.48 for men aged 50 to59, 1.609 for men aged 60 to 69years, 2 for men 
aged 70 to79 and 2.47 for men aged 80 to 89.  Our results were found to be 
similar to their results. 
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(Fig.3) 
 
Study conducted at the department of biochemistry punjagutta34 India 
has also shown that Indian males have very low serum PSA concentrations 
compared with men from other Asian countries. Our study also shows low 
age specific PSA concentrations than men from other Asian countries 
(Fig.3). 
 
 
 
 
 
 
  
 
Comparative data’s are shown in table - 5                       
                   
 
Table – 5 
 
 
Age specific PSA -95 Percentile value 
 
 
 
Author (year, n) Population  <40 
yrs 
40-49 
yrs 
50-59 yrs 60-69 
yrs 
70-79 
yrs 
>80 
 Yrs 
Morgan et al.33 
1996 
N=b1673 
W =1802 
Afro Americans US 
Whites 
    - 2.4 
2.1 
6.54 
3.6 
11.3 
4.3 
12.5 
5.8 
    - 
Dalkin et al42 
1993,n=728 
           USA   3.5 5.4 6.3  
Oesterling 35et al 
1993 
N =471 
Whites      - 2.5 3.5 4.5 6.5      - 
Oesterling et al32  
1995.N=286 
Japanese     - 2 3 4 5.0     - 
Cooney KA43. 2001 
 N =943 
Michigan  
African-American  
  2.36   5.59 
Wu TT et al41 2000 
N =1,236 
Chinese   4  6  
Wang MZ15. 2003 
N=1,096 
Chinese  1.21 
 
1.23 2.35 3.20 3.39     - 
Kehinde EO et al 14 
2005 
 N=396 
Arab  0.9  2.7 5.5  
Our study 2005 
N=117 
Indian  0.564 1.142 1.69   
 
 
  
 
Anderson et al4 4 found that the published age specific 
reference ranges were too high for men younger than 60 and too 
low for men aged 70 –79 years. Their proposed upper limit of 
normal were 1.5 ng/ml for men 40-49 years, 2.5 ng/ml for 50 to 
59 years, 4.5 ng/ml for 60-69 years, and 7.5 ng/ml for men 70-79 
years. Even though our study population did not include men in 
there 70s, our study also shows low age specific reference values 
for men less than 69 years.  
 
In our study the mean value of serum PSA was 0.49 for 40 
– 49 years, 0.99 for 50-59 years and 1.27 for 60-69 years (Fig.4). 
There was an increase in mean PSA value with increase in age, 
and the difference was statistically significant.  
Kamal BA et al1 7  showed similar results in Saudi men.  The 
mean values were 0.87 for men 40-49 years, 1.36 for men 50-59 
years, 1.81 for men 60-69 years, 2.32 for men 70-79 years and 2.36 
for men 80-89 years.  
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(Fig.4) 
 
 
Battikhi MN et al1 6  studied age-specific reference ranges of 
TPSA and FPSA. Recommended values of TPSA and FPSA were, 
2.3 and 0.51 ng/ml for 30-34 y; 2.9 and 0.59 ng/ml for 35-39 y; 
3.2 and 0.63 ng/ml for 40-44 y; 3.75 and 0.71 ng/ml for 45-49 y; 
3.8 and 0.83 ng/ml for 50-54 y; 3.75 and 0.96 ng/ml for 55-59 y; 
4.3 and 1.26 ng/ml for >60 y old respectively. Similar to our 
study (Fig.5) they showed a continuous increase in TPSA. They 
also showed increase in FPSA with a significant correlation 
(P<0.001, P<0.05) 
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Fig.5 
 
 
Only two variables are shown in Fig.5. Serum PSA range in 
the age group 60 – 69 was not shown due to the small size (9%). 
 
 
El galley et al36 (largest analysis) supported the use of age 
specific reference ranges because of demonstrated increase in 
sensitivity and increase in specificity in older men and 
subsequent decrease in biopsy in older men. 
 
 
 
40 –49 y 
 
50 –59 y 
 Catalona WJ et al13 found that percent free PSA and age-
specific PSA cutoffs enhanced PSA specificity for cancer 
detection, but percent free PSA maintained significantly higher 
sensitivities. They showed that the %fPSA and PSAD were more 
sensitive (95% sensitivity) and age-specific PSA cutoffs missed 
20% to 60% of cancers in men older than 60 years of age.  The 
prostatic volume (KUBU) in our study ranges from 16 – 28ml. 
 
Ito K et al12 also found that using the age-specific PSA 
reference range the sensitivity, specificity, and efficiency 
increased to 92.4%, 91.2%, and 84.3%, respectively.  The 
diagnostic efficiency of the age-specific PSA reference range 
was optimal with cutoff values of 3.0, 3.5, 4.0, 4.0, and 7.0 
ng/mL in subjects 60 to 64, 65 to 69, 70 to 74, 75 to 79, and 
older than 80 years of age, respectively. All of the cases of 
prostate cancer detected were clinically significant. 
Studies32,35 ,42,44 have clearly shown the importance of age 
specific reference range and the importance of knowing the race. 
The clinical meaning of a given PSA varies from one race to the 
other.  
 Investigators have recommended age specific prostate 
specific reference ranges based on ethnicity3. (Table-6)  
 
 
Recommended Age Specific Prostate Specific Reference Ranges3. 
                                              (Controversial) 
 
 
Table – 6 
 
 
  
Age 
 
Years 
White 
ng/ml 
Specificity
% 
Black 
ng/ml 
Specificity
% 
Asian 
ng/ml 
Specificity
% 
40-49 
 2.5 95 2.0 93 2.0 95 
50-59 
 3.5 95 4.0 88 3.0 95 
60-69 
 4.5 95 4.5 81 4.0 95 
70-79 
 6.5 95 5.5 78 5.0 95 
 
  
 
Osterling et al4 5  concluded that by using age specific reference 
ranges for serum PSA the sensitivity decreased by 9%, the 
specificity increased by 11% and the over all positive predictive 
value increased by 5%. 
 
      SUMMARY 
 
Aim  
To determine age-specific reference ranges for serum 
prostate-specific antigen (PSA) concentration in South Indian 
men. 
Study design  
Cross sectional study.  
Setting    
This study analyzed the PSA value of 117 subjects with out 
lower urinary tract symptoms during the period October 2003 to 
September 2005 at Government General Hospital. Chennai -3 
 
Inclusion criteria 
1. Individuals attending Urology clinics for minor illness 
2. Normal healthy volunteers.  
Exclusion criteria    
1. Subjects with history of lower urinary tract symptoms 
2. Subjects with history of recent urethral 
instrumentation. 
3. Subjects with history of recent catheterization 
4. Patients with history of Prostatitis  
 Data collection 
 
Our study group consisted of 117subjects belonging to the 
subpopulation of Chennai from south India of different age 
groups ranging from 40 to 69 years. Detailed history was taken 
and a complete clinical examination was done. Blood 
biochemical analysis and urine analysis was done for all patients. 
Ultrasound KUBU, digital rectal examination was done in all 
selected subjects. Complete questionnaire is shown in appendix 1 
Serum PSA was estimated29 using ELISA, and Bayer ADVIA 
centaur assay kits (last 25 patients).  
 
Case definitions  
 
Subjects referred to urology department for evaluation of 
renal cyst, back pain, renal microlith, infertility were included in 
the study. Three cases of renal calculi with out urinary tract 
infection were also included in the study. Healthy volunteers 
(hospital workers, patient’s attenders) after through examination 
and history taking were also included in the study group. 
 
 
  
Statistical analysis  
 
Statistical analysis by Student ‘t’ test. Confidence intervals 
mean, minimum and maximum values were calculated for each 
decade of age group. Confidence interval high represents 95th 
percentile value in a given group. 
 
Results During the study period October 2003 to September 
2005, serum total PSA of 117 subjects with out lower urinary 
tract symptoms and any other major clinical illness between the 
age group 40 to 69 years were analyzed. 
 
Using the 95th percentile CI, the recommended age-specific 
reference ranges of total PSA values were as follows: for the age 
group 40 – 49 years 0.564 ng/ml, 50-59years 1.142 ng/ml 
respectively, and for the age group 60-69years serum PSA 95th 
percentile value is 1.69 ng/ml. The minimum value of total serum 
PSA detected was 0.05 ng/ml and the maximum value of serum 
PSA was 2.30 ng/ml. 
                                                                                                                
 The mean PSA value increased from 0.49 for men aged 
between 40to49 years to 1.27 for men aged between 60-69 years. 
The increase was statistically significant (p =0.000). 
 
 
The mean total PSA value increased from 0.99 for men 
aged between 50 to59 years to 1.27 for men aged between 60 to 
69 years. But the increase was not statistically significant (P 
=0.190), this may be because of the small sample size (9.4%) in 
the age group 60 to 69 years. Serum PSA was detected in the sera 
of all the 117 subjects 
                               
  
 
CONCLUSION 
 
 
 
1. The serum PSA concentration directly correlates with the 
patient’s age. Thus, rather than relying on a single 
reference range for men of all age groups, it is more 
appropriate to have age-specific reference ranges.  
2. Age-specific reference ranges have the potential to make 
serum PSA a more discriminating tumor marker for 
detecting clinically significant cancers in older men and to 
find more potentially curable cancers in younger men.  
3. Age and race specific reference range will help in 
developing specific algorithm for different population to 
detect adenocarcinoma of the prostate at an earlier stage.  
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 APPENDIX I 
PROFORMA 
 
Age-specific reference ranges for serum prostate-specific antigen 
(PSA) concentration in south Indian men.  
Name :  
 
Age : 
 
I.D. No. : 
 
Diabetic  :  Yes   No 
 
Hypertensive :  Yes   No 
 
Smoker  :  Yes   No 
 
Alcoholic  :  Yes   No 
 
Surgery  :  Yes   No 
 
Medication  :  Yes   No 
 
Inclusion criteria 
3. Individuals attending urology clinics for minor illness 
4. Normal healthy volunteers   
Exclusion criteria    
5. Subjects with history of lower urinary tract symptoms 
6. Subjects with history of recent urethral instrumentation 
7. Subjects with history of recent catheterization 
 8. Patients with history of Prostatitis  
 
 
Investigations : 
Hb      Blood  Urea 
Urine  Albumin     Sugar 
  Sugar      Creatinine  
  Deposits 
USG  KUBU 
Serum PSA 
 
Clinical Examination 
 Per Rectal Examination 
Prostate :  Consistency  
Grade 
 
 
 
 
  
 APPENDIX - II 
MASTER CHART 
 
S. 
No. Name Age Diabetic Hypertensive Surgery Medications 
S.PSA 
ng/ml 
1.  Thangaraj 44 - - - - 0.79 
2.  Muthu 48 - - - - 0.54 
3.  Sundar 44 - - - - 0.74 
4.  Murugan 42 - - - - 0.23 
5.  Elappan 45 - - - - 0.67 
6.  Kandasamy 46 - - - - 0.87 
7.  Mani 40 - - - - 0.40 
8.  Annamalai 44 - - - - 0.35 
9.  Sekar 46 - - - - 0.50 
10.  Mohammed 47 DM - - Daonil  0.30 
11.  Padmanaban 44 - - - - 0.22 
12.  Pakirisamy 44 - - - - 0.48 
13.  Kumar 47 - - - - 0.40 
14.  Ranga Rajan 45 - - - - 0.05 
15.  Arjun 42 - - - - 0.35 
16.  Chandrasekar 40 - - - - 0.50 
17.  Shivalingam 46 - - - - 0.45 
18.  Srinivasan 44 - - - - 0.15 
19.  Subramani 45 - - - - 0.23 
20.  Sivakumar 44 - - - - 0.38 
21.  Ahmed Basha 45 - - - - 0.40 
22.  Thillai Govindan 47 - - - - 0.30 
23.  Seetharam 46 - - - - 0.50 
24.  Muniratnam 45 - - - - 0.30 
25.  Paneer 45 - - - - 0.40 
26.  Balakumar 46 - - - - 0.12 
27.  Venkatesh 43 - - - - 0.20 
28.  Muthusawmy 44 - - - - 0.30 
29.  Chandran 45 - - - - 0.25 
30.  Thangaraj 42 - - - - 0.25 
31.  Ramakrishnan 46 - - - - 0.30 
32.  Jaganathan 46 - - - - 0.45 
33.  Ramalingam 49 - - - - 0.20 
34.  Shankar 49 - - - - 1 
35.  Abdul Kareem 46 - - - - 0.78 
36.  Durai Raj 47 - - - - 0.76 
37.  Ganesan 47 - - - - 0.35 
38.  Mohan Raj 43 - - - - 0.82 
39.  Saunder 42 - - - - 0.21 
40.  Thangam 49 - - - - 1.10 
41.  Thirumurgan 48 - - - - 0.85 
42.  Raman 44 - - - - 0.35 
43.  Tholkapian 42 - - - - 0.70 
44.  Umapathy 45 - - - - 0.90 
45.  Baskaran  46 - - - - 0.80 
46.  Krishnamoorthy 47 - - - - 1.00 
47.  Muthaiah 48 - - - - 0.55 
48.  Abdul Razak 49 DM - - Diet Control 0.18 
 49.  Prabakaran 49 - - - - 0.75 
50.  Venkatesan 48 - - - - 0.72 
 
  
S. 
No. Name Age Diabetic Hypertensive Surgery Medications 
S.PSA 
ng/ml 
51.  Rajendren 58 - - - - 0.50 
52.  Kannappan 55 - - - - 0.36 
53.  Rangasamy 59 - - - - 0.58 
54.  Swamy 57 - - - - 0.40 
55.  Esupatham 52 - - - - 0.90 
56.  Jayamurthy 51 - - - - 0.50 
57.  Vetrivel 53 - - - - 0.59 
58.  Thripathy 58 - - - - 2.02 
59.  Veerasamy 58 - - - - 0.10 
60.  Muthupandian 55 - - - - 1.40 
61.  Subramanian 55 - - - - 1.65 
62.  Sa Mohammed 56 - - - - 0.75 
63.  Ratinavel 54 - - - - 1.25 
64.  Subramanian 59 - HT - Atenolol 2.30 
65.  Narayanasamy 57 - - - - 0.75 
66.  Sivakumar 58 - - - - 0.60 
67.  Govindasamy 56 - - - - 0.55 
68.  Shakir Ahamed 57 - - - - 0.80 
69.  Balaraman 59 - - - - 0.70 
70.  Durai Raj 54 - - - - 0.78 
71.  Rajagopal 55 - - - - 1.10 
72.  Mohammed 55 - - - - 0.90 
73.  Ramachadran 56 - - - - 0.90 
74.  Khader 54 - - - - 0.80 
75.  Govindan 55 - - - - 0.70 
76.  Arunachalam 56 - - - - 0.75 
77.  Poongavanam 50 - - - - 0.68 
78.  Jawahar 52 - - - - 0.60 
79.  Subramanian 53 - - - - 1.00 
80.  Nandalal 52 - - - - 0.70 
81.  Ardhanari 50 - - - - 1.44 
82.  Marimuthu 53 - - - - 0.95 
83.  Kamal Basha 54 - - - - 0.70 
84.  Mathews  55 DM - - Daonil 0.65 
85.  Senthamarai 56 - - - - 0.70 
86.  Malayandi 57 - - - - 0.60 
87.  Natarajan 56 - - - - 0.40 
88.  Govinda Rajan 58 - - - - 0.55 
89.  Krishna Murthy 59 - - - - 1.34 
90.  Mahalingam 58 - - - - 0.41 
91.  Amirtham 59 - - - - 1.10 
92.  Durai 53 - - - - 1.56 
93.  Desai 59 - - - - 0.80 
94.  Veeraragavan 58 - - - - 1.02 
95.  Subramani 58 - - - - 0.36 
96.  Ranganathan 57 - HT - Atenolol 2.05 
97.  Mannan 57 - - - - 2.01 
98.  Jayabal 59 - - - - 0.45 
99.  Thangaraj  56 - - - - 0.45 
100. Balakrishnan 57 - - - - 0.60 
  
 
S. 
No. Name Age Diabetic Hypertensive Surgery Medications 
S.PSA 
ng/ml 
101. Jayapal 56 - - - - 2.00 
102. Muthu 56 - - - - 2.20 
103. Chakaravathy 59 - - - - 1.70 
104. Jayavel  58 - - - - 1.95 
105. Mani  58 - - - - 2.20 
106. Razak 59 - - - - 1.80 
107. Rajagopalan 69 - - - - 0.50 
108. Govindan 65 - - - - 0.57 
109. Krishnamurthy 63 - - - - 1.34 
110. Mahalingam 69 - - - - 0.41 
111. Karunakaran 69 DM - - Daonil 0.90 
112. Krishnasamy 68 - - - - 1.85 
113. Ramani 66 - - - - 2.15 
114. Subramani 69 - - - - 2.10 
115. Perumal 68 - - - - 2.20 
116. John Mathews 63 - - - - 1.34 
117. Krishnan 60 - - - - 0.58 
 
 
